SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is surging on massive speculative volume, fueled by escalating geopolitical tensions and fears surrounding the Strait of Hormuz closure by Iran, with the community actively debating short squeeze potential due to high cost-to-borrow and low share availability, despite some warnings about the company's debt.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as a significant stake disclosure by hedge fund MMCAP International, coupled with a recent corporate update teasing partnerships with "even bigger" companies, fuels strong community speculation. Investors are actively discussing the company's disruptive optical interposer technology and its potential to address high-speed data demands within the booming AI and photonics sectors, anticipating an imminent revenue ramp and major collaborations.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors keenly await the outcome of a contentious city council vote in Independence, Missouri, regarding a crucial data center tax abatement, while simultaneously grappling with broader market pressure stemming from a competitor's recent disappointing earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as discussions are dominated by President Trump's recent military actions in Iran, sparking intense debate within the community regarding the conflict's strategic purpose versus claims of it being a distraction from domestic issues such as the Epstein files.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB Inc. is trending lower following its earnings report, where robust quarterly results were overshadowed by cautious forward guidance and news of executive departures, prompting community discussion on whether the significant sell-off is an overreaction or a justified response to slowing growth concerns within the software sector.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment Inc. is trending due to a sharp sell-off following a Raymond James downgrade tied to the recompete of a significant $1.4 billion Space Force contract. However, the community largely views this as an overreaction, actively buying the dip while highlighting strong drone demand amid global tensions and anticipating a positive earnings report.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings Inc. is trending sharply upward following Nvidia's multi-billion dollar strategic investment and partnership aimed at advancing optical interconnects for next-generation AI data centers. The community is excitedly discussing Lumentum's dramatic price appreciation and its pivotal role in the burgeoning AI infrastructure, despite some voicing concerns over its rapidly escalating valuation.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT is a major talking point as its high-energy laser technology demonstrates proven effectiveness in Israel's Iron Beam defense system, igniting community speculation about substantial new defense contracts and its central role in the evolving landscape of directed energy solutions. This surge in interest is further amplified by the company's expanded manufacturing capabilities to meet growing global demand for advanced laser weaponry.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster Inc. is trending after reporting exceptionally strong Q4 earnings, significantly beating revenue and EPS estimates while achieving GAAP profitability. The community is actively discussing its strong gross margins, robust forward guidance, and the strategic acquisition of StereoLabs, which positions the company as a leading full-stack sensing and perception platform for the rapidly expanding Physical AI market.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

Dave Inc. is trending following its strong Q4 '25 earnings report, which included substantial revenue and EPS growth and an increased $300 million share repurchase authorization. The community is actively discussing potential analyst upgrades and a short squeeze, believing the fintech is significantly undervalued given its robust financial performance and tight share float.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The patent in question is about new chemical versions of psilocybin to treat mental health conditions such as depression, anxiety, and post-traumatic stress disorder.</li><li>Enveric identified that Gilgamesh’s petition may target claims that could be relevant to another family of patents owned by the company.</li><li>These patents are aimed at the treatment of depression and anxiety, and Enveric noted that the company has licensed them to third parties for development.</li></ul>Enveric Biosciences Inc. (ENVB) on Wednesday announced that Gilgamesh Pharmaceuticals has withdrawn a challenge against the company’s patent.Enveric stated that following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.<a href="https://stocktwits.com/symbol/ENVB">Enveric shares</a> were up more than 4% in Wednesday’s opening trade.<h2 class="st-heading-2">What Is The Patent In Question About?</h2>The patent in question is about new chemical versions of psilocybin to treat mental health conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD).Gilgamesh filed a challenge against the patent in August 2025. Subsequently, AbbVie Inv. (ABBV) acquired bretisilocin from the company in a deal valued at up to $1.2 billion. Gilgamesh notified the U.S. Patent and Trademark Office (USPTO) that it had become a wholly-owned subsidiary of an entity owned by AbbVie.AbbVie filed a request with the USPTO in October to withdraw the post-grant review (PGR) petition filed by Gilgamesh.Enveric identified that Gilgamesh’s petition may target claims that could be relevant to another family of patents owned by the company. These patents are aimed at the treatment of depression and anxiety, and Enveric noted that the company has licensed them to third parties for development.Under its license terms, the company is eligible to receive aggregate upfront, development, and sales milestones potentially totaling up to $205 million, in addition to royalties on future sales.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user on Stocktwits termed the withdrawal of the petition against Enveric as “huge news.”<stembedurl>https://stocktwits.com/Luckyjs38/message/645825647</stembedurl><a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 39% year-to-date and 84% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vnda-stock-rises-after-fda-accepts-imsidolimab-gpp-treatment/cZRyPfnRIGR">Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

Equity

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological...

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

<ul class="summary-bullets"><li>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways.</li><li>The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.</li><li>Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.</li></ul>Enveric Biosciences Inc. (SOPA) shares gained over 7% in Monday’s pre-market trade after the company announced that it has been issued a patent that covers novel molecules with likely applications for the treatment of neuropsychiatric conditions.The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Licensing Opportunity</h2>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways. The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.<h2 class="st-heading-2">Patent Details</h2>Enveric stated that the molecules covered by this patent are based on known compounds with relevant pharmacological activity. It added that these compounds are chemically altered to improve efficacy while reducing side effects compared to existing compounds.“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Enveric CEO Joseph Tucker.Enveric is a Massachusetts-based biotechnology company focused on developing small-molecule neuroplastogenic therapeutics for the treatment of psychiatric and neurological disorders.<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 99.6% year-to-date and 99.5% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paul-krugman-warns-2026-worse-for-small-businesses/cL75twFRExT">Paul Krugman Warns 2026 Will Be Worse For Small Businesses, A Month After Small Firms Cut 120,000 Jobs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ENVB Stock Rising Today?

The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

<ul class="summary-bullets"><li>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted.</li><li>By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space.</li><li>Enveric’s stock surged 106% in Wednesday’s premarket.</li></ul>Enveric Biosciences (ENVB) stock is drawing investors' attention on Wednesday after the company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application covering its EVM301 Series of molecules.<a href="https://stocktwits.com/symbol/ENVB/sentiment">Enveric’s stock</a> traded over 106% higher in Wednesday’s premarket.&nbsp;<h2 class="st-heading-2">Patent Focus and Potential</h2>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted, providing Enveric with intellectual property protection for its neuroplastogenic compounds.“We believe EB-003 holds great potential as the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects, while being specifically designed to promote neuroplasticity and minimize hallucinogenic effects, allowing administration in outpatient setting,” said Joseph Tucker, CEO, Enveric.&nbsp;By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space, particularly for patients with limited therapeutic options. The patent also enhances the company’s ability to pursue future research and commercialization of its EVM301 compounds.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>The stock was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:936/103;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_10_090740_png_d70c080d0b.webp" alt="ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits" width="936" height="103"><figcaption>ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said that if the drug proves safe and effective, a potential buyout exceeding $1 billion could be possible.&nbsp;<stembedurl>https://stocktwits.com/Luckyjs38/message/638708222</stembedurl>Another user expressed optimism about the low float and fresh IP update.&nbsp;<stembedurl>https://stocktwits.com/Caicong/message/638709397</stembedurl>ENVB stock has lost over 90% of its value year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-beat-stock-rocket-72-in-pre-market-today/cLIH2RhREV2">Why Did BEAT Stock Rocket 72% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various substances are placed on cooling blocks in the PCR laboratory of the State Office for Agriculture, Food Safety and Fisheries.

Why Did ENVB Stock More Than Double In Value Today?

The company received a Notice of Allowance from the United States Patent and Trademark Office for its patent application.

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During J.P. Morgan Week 2026

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

ENVB
Enveric Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ENVB News

ENVBEnveric Biosciences Inc